An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer
Urologia Internationalis · 2024
DOI: 10.1159/000536321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, 2024. Verfasst von Moritz J Reike und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
The aim of the study was to determine the adaption of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC) in Germany, Austria, and Switzerland and especially underlying reasons for potential low adherence to guidelines.
Methods
We conducted a non-validated survey among 336 urologic departments in Germany, Austria, and Switzerland. RedCap questionnaires were electronically distributed and included 23 items concerning the general NAC administration standards and guideline compliance in patient counseling regarding the actual treatment.
Results
The return rate of the questionnaire was 19.1% (63/336). Although 45 departments (71.4%) claim to perform NAC as the standard of care, only 49% of eligible patients actually receive NAC. An advanced disease stage (≥cT3) and a high tumor volume were mentioned to support the application of NAC, whereas 35% of responders worry about deterioration of patients’ preoperative status due to NAC. Furthermore, 26.7% of respondents are concerned about the low extent of survival benefit.
Conclusion
Application of NAC in eligible MIBC patients in Germany, Austria, and Switzerland remains low. Although the majority of urologic departments discuss NAC and acknowledge the need for intensified treatment in advanced disease stages, not all eligible patients will actually receive NAC before radical cystectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
- Department of Urology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.
- Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
- Department of Urology, University of Regensburg, Caritas St. Josef Hospital, Regensburg, Germany.
- Department of Urology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Zitieren
APA
Reike, M. J., Reicherz, A., Tully, K. H., Bahlburg, H., Maas, M., Bach, P., Klümper, N., Eckstein, M., Hartmann, A., Breyer, J., Erben, P., Bolenz, C., Noldus, J., Berg, S., & Roghmann, F. (2024). An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer. Urologia Internationalis. https://doi.org/10.1159/000536321
Vancouver
Reike MJ, Reicherz A, Tully KH, Bahlburg H, Maas M, Bach P, et al. An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer. Urologia Internationalis. 2024. doi:10.1159/000536321
BibTeX
@article{Reike2024,
author = {Reike, Moritz J and Reicherz, Alina and Tully, Karl H and Bahlburg, Henning and Maas, Moritz and Bach, Peter and Klümper, Niklas and Eckstein, Markus and Hartmann, Arndt and Breyer, Johannes and Erben, Philipp and Bolenz, Christian and Noldus, Joachim and Berg, Sebastian and Roghmann, Florian},
title = {An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer},
journal = {Urologia Internationalis},
year = {2024},
doi = {10.1159/000536321}
}
EUVIMED